Klin Farmakol Farm. 2004;18(3):183-184
Studie VALUE - valsartan verzus amlodipin v léčbě hypertenze
- 1 I. interní kardioangiologická klinika FN u sv. Anny v Brně
- 2 II. interní klinika FN u sv. Anny LF MU, Brno
Keywords: hypertension, amlodipine, valsartan.
Published: December 31, 2004 Show citation
Studie VALUE srovnávala u 15 245 nemocných s hypertenzí valsartan a amlodipin samostatně i v kombinaci s jinými antihypertenzivy. Primární cíl (srdeční úmrtnost a nemocnost) byl ovlivněn oběma léky stejně, amlodipin byl účinnějąí v poklesu TK v prvních 6 měsících, s menąím výskytem mozkových příhod a infarktu myokardu, naopak po valsartanu byl významně niľąí výskyt nového diabetes mellitus.
THE VALSARTAN ANTIHYPERTENSIVE LONG-TERM USE EVALUATION TRIAL
In VALUE Trial were compared valsartan and amlodipine as monotherapy or combination in 15 245 hypertensive patients. Primary endpoint (cardiac mortality and morbidity) was not different, amlodipine was more efficient during first 6 months, with lower new stroke and myocardial infarction occurence, on the contrary new diabetes mellitus was lower after valsartan treatment.
Download citation
References
- Kjeldesen SE, Julius S, Brunner HR et all. Characteristics of 15 314 hypertensive patients at high coronary risk. The VALUE trial. Blood Press 2001; 10: 83-91.
Go to original source... 
Go to PubMed... - Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. Go to original source... Go to PubMed...
- Mann J, Julius S. for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluaion (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176-183. Go to original source... Go to PubMed...
- The ALLHAT Officers ond Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. Go to original source... Go to PubMed...
- Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
- Weber MA, Julius S, Kjeldsen SE, et al: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363: 2047-2049. Go to original source... Go to PubMed...
- Zanchetti A for the Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1053. Go to original source... Go to PubMed...